Global Immune Checkpoint Inhibitors Market Research Report: Forecast (2025-2030)
Immune Checkpoint Inhibitors Market - By Drug Class (PD- 1 (Opdivo (Nivolumab), Keytruda (Pembrolizumab)), PD- L1 (Tecentriq (Atezolizumab), Bavencio (Avelumab), Imfinzi (Durvaluma...b), CTLA- 4 (Yervoy (Ipilimumab)), By Application (Melanoma, Hodgkin Lymphoma, Renal Cell Cancer, Urothelial Cancer, Non-Small Cell Lung Cancer (NSCLC), Others (Head & Neck Cancers, etc.)), By End-User (Hospitals, Clinics, Specialty Cancer Centers) and others Read more
- Healthcare
- Jun 2022
- 198
- PDF, Excel, PPT
Market Definition
The Immune Checkpoints are the basic part of the immune system. The main function of these checkpoint inhibitors is to intercept the immune checkpoint inhibitors from being robust so that it can easily prevent the healthy cells present in the body. Moreover, the inhibitors engage when proteins on the surface of immune cells known as T cells recognize and tie up to partner proteins on the other cells, like tumor cells. These proteins are also known as ‘Immune Checkpoint Proteins.’ So, when the checkpoint and partner proteins bind together, they send an ‘Off’ signal to the T cells. It helps in preventing the immune system from being destroyed by the cancer.
The checkpoint inhibitors work by releasing a natural brake on the immune system so that the immune cells identify and attack tumors. This therapy is also known as ‘Checkpoint Blockage’ as the molecule acts as a brake on immune cells – the checkpoint – is blocked by the drug.
Market Insights & Analysis: Global Immune Checkpoint Inhibitors Market (2025-30):
The Global Immune Checkpoint Inhibitor Market size was valued at around USD 51.2 billion in 2023 and is projected to grow at a CAGR of 15.6% during the forecast period of 2025-30. The growth of the market has transformed the treatment of cancer by combining the immune system of the body in order to target and destroy cancer cells. The industry of immune checkpoint inhibitors has observed substantial growth due to continuing research, clinical trials, and a rise in the number of approved therapies. Moreover, the commonness of various types of cancers such as breast, lung, cervical, bladder, melanoma, and Hodgkin lymphoma is leading to the adoption of immune checkpoint inhibitor therapies.
Report Coverage | Details |
---|---|
Historical Years | 2020-23 |
Base Years
|
2024
|
Forecast Years
|
2025-30
|
Market Value in 2023 | USD 51.2 Billion |
CAGR (2025-30) | 15.6% |
Leading Region | North America |
Top Key Players | AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bluebird Bio, Inc., Bristol Myers Squibb, CARsgen Therapeutics, Eli Lilly and Company, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Others |
Key Report Highlights |
|
*Boost strategic growth with in-depth market analysis - Get a free sample preview today!
Moreover, the rising awareness among patients regarding the advantages of checkpoint inhibitors such as minimum side effects & targeted therapeutic effects is another significant factor aspect fueling the demand for immune checkpoint inhibitors across the globe. As a result, it is attracting huge funding from multiple biotech companies, pharmaceuticals, universities, and cancer centers in the research and development of more effective immune checkpoint inhibitors, and thriving the overall growth of the industry.
However, the research and development require heavy expenses, also the lack of awareness among people for using these immune checkpoint inhibitors, mainly in developing regions hampers the expansion of the immune checkpoint inhibitors industry across the world.
Global Immune Checkpoint Inhibitors Market Driver:
Rising Prevalence of Cancer Cases Across the Globe Drives the Global Immune Checkpoint Inhibitors Market Growth- There are numerous reasons that thrives the demand for immune checkpoint inhibitors across the globe. One of them is the increasing commonness of cancer cases. The growing number of people diagnosing with cancer is surging notably with each successive year and fueling the demand for effective cancer treatment options. The immune checkpoint inhibitors are considered as a favorable approach in cancer treatment.
Thus, the rising population of cancer patients is fueling the demand for targeted and effective therapies like immune checkpoint inhibitors, and this factor is likely to continue in the forthcoming years and drive the growth of the industry.
Global Immune Checkpoint Inhibitors Market Challenge:
High Cost of Treatment Hinders the Expansion of the Immune Checkpoint Inhibitors Global Market- One of the major and notable factors hampering the growth of the Immune Checkpoints Inhibitors Market is the high cost correlated with cancer treatment. Immune Checkpoint Inhibitors like nivolumab, and pembrolizumab, are often overpriced at premium prices due to substantial investments in research and development, higher cost of clinical trials, and complex manufacturing procedures as well. The cost of a single course of treatment can reach $10,000, making it extremely expensive for several patients as well as healthcare systems, especially in low, and middle-income countries. Moreover, the cost of these therapies not only includes the drugs, but are also associated with medical care. In some regions, limited reimbursement policies also add a financial burden on the people. Consequently, it remains a notable challenge for the expansion of the industry.
Global Immune Checkpoint Inhibitors Market Opportunity:
Introduction of New Immune Checkpoint Inhibitors Fueling the Growth of the Industry- The success rate of cancer has increased because of the constant advancements in the therapeutic results, resulting to more efficient methods of treatment. Moreover, it is an achievement that has extended the comprehension of the disease’s pathophysiology, the development of efficient plans to address them as well as the tumor cell activities.
In addition, there are several manufacturers who are now manufacturing immune checkpoint inhibitors that are specifically designed to target and impede certain molecules, Furthermore, medicines focusing on specific immune regulatory checkpoints, like programmed death-1, and programmed death ligand-1 and 2, including Atezolimumab, Nivolumab, and Pembrolizumab, are being used for the treatment of non-small-cell lung cancer. Thus, the evolution in the new checkpoint inhibitors is expected as a profitable opportunity for the expansion of Immune Checkpoint Inhibitors in the upcoming years.
Global Immune Checkpoint Inhibitors Market Trend:
Growth of Combination Therapies Propelling the Global Immune Checkpoint Inhibitors Market- A notable trend in the Immune Checkpoint Inhibitors Market is the rise of combination therapies. There are several researchers in the industry who are constantly combining immune checkpoint inhibitors with other treatments. It includes radiation, chemotherapy, and targeted therapies. Moreover, combination therapies have shown enhanced results in several cases. They minimize resistance and improve the outcomes of patients. Furthermore, as clinical trials continue to support these benefits, more companies are investing in these areas. Thus, the trend of combining treatments is estimated to drive further innovation and market growth.
Global Immune Checkpoint Inhibitors Market (2025-2030): Segmentation Analysis
The Global Immune Checkpoint Inhibitors Report study of MarkNtel Advisors evaluates & highlights the major trends and influencing factors in each segment. It includes predictions for the period 2025–2030 at the global level. Based on the analysis, the market has been further classified as:
Based on Drug Class:
- PD- 1
- Opdivo (Nivolumab)
- Keytruda (Pembrolizumab)
- PD- L1
- Tecentriq (Atezolizumab)
- Bavencio (Avelumab)
- Imfinzi (Durvalumab)
- CTLA- 4
- Yervoy (Ipilimumab)
Out of all the drug classes, PD-1 inhibitors are estimated to lead the industry by holding the largest share in the Global Immune Checkpoint Inhibitors Market from 2025 to 2030.. It is accredited mainly due to the massive investments initiated by governments in various research & development activities for bringing innovations in PD-1 inhibitors like Opdivo (Nivolumab) & Keytruda (Pembrolizumab), combined with rapid approvals from regulatory associations. Also, with the instant rise in the influx of patients suffering from cancer, the prescription for Pembrolizumab & Nivolumab drugs also expanding and boosting the Immune Checkpoint Inhibitors Global Market.
Besides, with the acceptance of Pembrolizumab by the Food & Drug Association (FDA) owing to its productivity in addressing indications like Melanoma, Non–Small Cell Lung Cancer (NSCLC), Head & Neck Squamous Cell Cancer (HNSCC), and others, the demand for PD-1 exhibitors has escalated swiftly, i.e., playing a prominent role in augmenting the overall market growth.
Furthermore, the strong presence of dominating market participants as well as collaborations with academic institutions, and increasing emphasis on personalized medicine, and precision oncology further fuels the growth rate of the inhibitors in the North American region. Plus, the incidences of allergic reactions from other drug cases like CTLA-4 inhibitor, Yervoy (Ipilimumab), is another aspect demonstrating greater inclination of patients toward PD-1 and, in turn, promoting the expansion of the Immune Checkpoint Inhibitors Market globally.
Based on the Application:
- Melanoma
- Hodgkin Lymphoma
- Renal Cell Cancer
- Urothelial Cancer
- Non-Small Cell Lung Cancer (NSCLC)
- Others (Head & Neck Cancers, etc.)
Out of them, the Non-Small Cell Lung Cancer segment is expected to occupy the largest share in the Global Immune Checkpoint Inhibitors in the forthcoming years. Also, there is a rapid increase in incidences and mortality rates of lung cancer in the world, along with the surge in adoption of checkpoint inhibitors as a standard treatment option, favorable clinical results, and survival benefits in advanced stages thrive the growth of Non-Small Cell Lung Cancer segment in the global industry. The rising commonness of non-small cell lung cancer cases, and increasing research and clinical trials for novel checkpoint inhibitors in lung cancer further fuel the growth rate of the lung cancer segment.
Global Immune Checkpoint Inhibitors Market (2025-30): Regional Projection
Geographically, the Global Immune Checkpoint Inhibitors Market expands across:
- North America
- South America
- Europe
- Middle East & Africa
- Asia-Pacific
Among all these regions, the North America region dominated the Immune Checkpoint Inhibitors Market in the previous year and is expected to maintain its dominance in the upcoming years as well. In the North American region, there is an availability of well-established healthcare infrastructure, high adoption of advanced therapies, and the surge in demand for effective treatment drives the growth of immune inhibitors in the region.
Moreover, it is augmented due to the rising commonness of cancer cases in the region, along with advanced healthcare infrastructure and strong Research & Development activities. Plus, the availability of leading pharmaceutical companies as well as the availability of innovative cancer treatments further propels the growth of the industry. Additionally, supportive government policies and remarkable investments in cancer research contribute to the extensive adoption of immune checkpoints in the North American region. Also, the region’s leadership in the industry highlights its central role in advancing the treatment of cancer.
Global Immune Checkpoint Inhibitors Industry Recent Developments:
- In February 2024, AbbVie Inc., came together with Tentarix’s Tentacles to develop new multifunctional biologics in opposed to one target in oncology and another in immunology.
- In July 2023, AstraZeneca Plc, proliferated it oncology by initiating new clinical trial new clinical trial to assess the amalgamation of its PD-L1 inhibitor with another cancer treatment. It is one of the remarkable strategic moves that aims to improve the effectiveness of its immune checkpoint inhibitors in treating solid tumors.
Gain a Competitive Edge with Our Global Immune Checkpoints Inhibitors Market Report
- Global Immune Checkpoints Inhibitors Market Report by MarkNtel Advisors provides a detailed & thorough analysis of market size & share, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics & make informed decisions.
- This report also highlights current market trends & future projections, allowing businesses to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
- Global Immune Checkpoint Inhibitors Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.
*Reports Delivery Format - Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address.
Frequently Asked Questions
- Introduction
- Research Process
- Assumption
- Market Segmentation
- Market Definition
- Executive Summary
- Global Immune Checkpoint Inhibitors Market Trends & Insights
- Global Immune Checkpoint Inhibitors Market Regulation & Policy, By Country
- Global Immune Checkpoint Inhibitors Market Dynamics
- Growth Drivers
- Challenges
- Impact Analysis
- Global Immune Checkpoint Inhibitors Market Hotspot and Opportunities
- Global Immune Checkpoint Inhibitors Market Outlook, 2020- 2030
- Market Size and Analysis
- By Revenues in USD Million
- Market Share and Analysis
- By Drug Class
- PD- 1
- Opdivo (Nivolumab)
- Keytruda (Pembrolizumab)
- PD- L1
- Tecentriq (Atezolizumab)
- Bavencio (Avelumab)
- Imfinzi (Durvalumab)
- CTLA- 4
- Yervoy (Ipilimumab)
- PD- 1
- By Application
- Melanoma
- Hodgkin Lymphoma
- Renal Cell Cancer
- Urothelial Cancer
- Non-Small Cell Lung Cancer (NSCLC)
- Others (Head & Neck Cancers, etc.)
- By End-User
- Hospitals
- Clinics
- Specialty Cancer Centers
- By Region
- North America
- South America
- Europe
- Middle East & Africa
- Asia-Pacific
- By Company
- Competition Characteristics
- Revenue Shares
- Competitor Placement in MarkNtel Advisor’s Quadrant
- By Drug Class
- Market Size and Analysis
- North America Immune Checkpoint Inhibitors Outlook, 2020- 2030
- Market Size and Analysis
- By Revenues in USD Million
- Market Share and Analysis
- By Drug Class
- By Application
- By End-User
- By Country
- The US
- Canada
- Mexico
- Market Size and Analysis
- South America Immune Checkpoint Inhibitors Outlook, 2020- 2030
- Market Size and Analysis
- By Revenues in USD Million
- Market Share and Analysis
- By Drug Class
- By Application
- By End-User
- By Country
- Brazil
- Rest of Latin America
- Market Size and Analysis
- Europe Immune Checkpoint Inhibitors Outlook, 2020- 2030
- Market Size and Analysis
- By Revenues in USD Million
- Market Share and Analysis
- By Drug Class
- By Application
- By End-User
- By Country
- The UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Market Size and Analysis
- Middle East & Africa Immune Checkpoint Inhibitors Outlook, 2020- 2030
- Market Size and Analysis
- By Revenues in USD Million
- Market Share and Analysis
- By Drug Class
- By Application
- By End-User
- By Country
- South Africa
- GCC
- Rest of Middle East & Africa
- Market Size and Analysis
- Asia-Pacific Immune Checkpoint Inhibitors Outlook, 2020- 2030
- Market Size and Analysis
- By Revenues in USD Million
- Market Share and Analysis
- By Drug Class
- By Application
- By End-User
- By Country
- China
- Japan
- India
- Australia
- South East Asia
- Rest of Asia Pacific
- Market Size and Analysis
- Global Immune Checkpoint Inhibitors Market Key Strategic Imperatives for Success and Growth
- Competitive Outlook
- Competition Matrix
- By Application Portfolio
- Brand Specialization
- Target Markets
- Target by Applications
- Research & Development
- Strategic Alliances
- Strategic Initiatives
- Company Profiles (Business Description, By Application Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca PLC
- Bluebird Bio, Inc.
- Bristol Myers Squibb
- CARsgen Therapeutics
- Eli Lilly and Company
- GlaxoSmithKline PLC
- Merck & Co., Inc.
- Novartis International AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.
- Others
- Competition Matrix
- Disclaimer